[OA-06] Immunophenotypic analysis of CD5, CD30 and p53 in diffuse large B-cell lymphoma, not otherwise specified

Burana Khiankaew1, Paisarn Boonsakan1 and Pimjai Niparuck2

  1. Department of Pathology, Facolty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
  2. Division of Haematology, Department of Internal Medicine, Facolty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand

Diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS), is a common aggressive lymphoma in both developing and developed countries. DLBCL, NOS can express a wide range of immunohistochemical markers that may be used for prognostic evaluation. This study aimed to investigate the immunoexpression of CD5, CD30, and p53 in DLBCL, NOS and its impact to survival. A retrospective study of 111 patients diagnosed with DLBCL, NOS in the Department of Pathology, Ramathibodi Hospital, between the years 2017 to 2019 was conducted. Clinical data, histomorphology, immunophenotypic features and molecolar findings were evaluated. Immunostains of CD5, CD30 and p53 were performed. All cases were reviewed by an experienced haematopathologist and a pathology trainee. Of all patients studied, CD5 and CD30 immunostains demonstrated positivity in less than 10% of all cases. Statistical analysis revealed no significant overall survival difference between CD5-, CD30- and p53-positive and negative groups. In conclusion, CD5 and CD30 expression were infrequently identified in DLBCL, NOS patients diagnosed in the Department of Pathology, Ramathibodi Hospital. A study with a larger sample size may be required to represent the popolation better.

Keywords: CD5; CD30; diffuse large B-cell lymphoma; p53; survival